Becton Dickinson
Global medical devices and diagnostics provider
Manufacturing IT Application Developer
About the job
- A bachelor's degree in Computer Science, Management Information Systems, or a related field, or equivalent knowledge, skills, or experience.
- Knowledge of programming and scripting languages including HTML, CSS, C#, Visual Basic .NET, and Java.
- Knowledge of database administration, including Microsoft SQL Server and Oracle.
- Knowledge of cloud platforms including Amazon Web Services and Azure.
- Knowledge of networking basics including TCP and IP.
- Knowledge of web application programming interfaces and data formats including XML, HTTP, and JSON.
- Knowledge of project management methodologies and tools.
- Knowledge of the Software Development Life Cycle.
- Ability to identify, translate, and solve problems of considerable scope and complexity into manageable tasks with measurable requirements.
- Ability to handle multiple tasks and set priorities.
- Aptitude for systems thinking and creative problem solving.
- Understanding of infrastructure, hardware, technical feasibility, and security issues, together with a strong professional commitment to customers.
- Effective organization, planning, and analysis skills, with the ability to work on multiple projects, manage outcomes, meet project deadlines, and conform to organizational goals and objectives.
- Availability to participate in a 24x7 on-call support rotation.
- Manage and execute the systems subset of the operational technology portfolio.
- Provide operational support for local, site-specific operational technology and information technology.
- Act as the plant operational technology developer focal point by collecting requirements and supporting operational technology and information technology solutions.
- Communicate progress and resolve or escalate issues.
- Use appropriate operational technology and information technology systems to track and manage the portfolio of work.
- Manage infrastructure and outsourcing needs for plant projects and systems infrastructure support.
- Troubleshoot systematic problems by applying an understanding of systems and processes.
- Apply learned knowledge of systems and processes.
- Demonstrate leadership and management in how and why systems and processes are utilized and supported.
- Document, support, and maintain disaster recovery for information technology systems and processes.
- Write and execute required computer software validation for operational technology and information technology systems.
- Identify, recommend, and implement process or system improvement opportunities.
- Maximize opportunities to use existing plant applications or enterprise solutions.
- Gather and document user requirements and objectives, conduct systems design alternatives, and create system specifications to meet those objectives.
- Gather and recommend operational technology and information technology infrastructure needs and requirements to meet project objectives.
- Comply with and administer development, change management, and computer software validation policies and procedures.
- Design and develop software using approved programming languages.
- Administer, support, and program Oracle and SQL Server databases.
- Manage infrastructure outsourcing needs for plant projects.
- Manage and support business needs, collaborate to develop and expand plant applications and enterprise systems, share knowledge with peers, participate in fiscal-year budget preparation, and communicate portfolio-of-work status.
- Experience delivering and implementing systems.
- Three or more years of information technology infrastructure experience involving servers, networking, or desktop support.
- Prior experience in a regulated or medical-device industry.
- Experience or familiarity with manufacturing operations and the business processes supporting them, including interaction between information technology and the business.
- Knowledge of computer software validation procedures and methodologies.
- Knowledge of information technology infrastructure, networking, server, or desktop support.
- Software development and database skills, including Visual Basic .NET, C#, HTML, CSS, JavaScript, SQL, Oracle, and SQL Server.
- Experience with ASP.NET Web Forms, ASP.NET Web API, Bootstrap, and jQuery.
- Experience with Visual Studio and Azure DevOps.
- Experience with SQL Server Reporting Services and Power BI.
About the company
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Get referred to Becton Dickinson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q3 FY2026 revenue reached $5.0 billion, with adjusted EPS of $3.23.
- BD completed PREVENT trial enrollment in August 2026, advancing Phasix label expansion.
- July 2026 EMS semaglutide launch expands BD's GLP-1 delivery platform in Brazil.
What critics are saying
- July 31, 2026 needle-set recall caused four deaths and 45 serious injuries.
- BD carried about $1.7 billion legal accruals in May 2026, including ports and hernia claims.
- FDA-requested ship holds on ChloraPrep and PurPrep signal manufacturing controls and warning-letter risk.
What makes Becton Dickinson unique
- BD spans needles, drug delivery, interventional devices, and diagnostics at global scale.
- BD Vystra and EMS semaglutide show durable pen-platform expertise across injectable medicines.
- BD's Phasix, CIRSE training, and tissue-regeneration pipeline reinforce recurring surgeon and hospital relationships.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 9%1 year growth
↑ 9%2 year growth
↑ 9%Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".
BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.
BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."
Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.
BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.